1. Introduction {#sec0005}
===============

The world is witnessing a new public health threat since the beginning of this year. Coronavirus disease 2019 (COVID-19), caused by the novel Coronavirus SARS-CoV-2, originated in Wuhan, China towards the end of last year and was declared by the World Health Organization (WHO) to be a 'Public Health Emergency of International Concern' (PHEIC) within a month of its emergence. Subsequently, it turned into an epidemic six weeks later ([@bib0340]). With more than six million affected and nearly four lakhs succumbing to the infection, WHO has termed it the largest infectious outbreak that the modern world has ever seen (WHO COVID-19 Situation Report, as on 15 June [@bib0390]). Fear, health anxiety, apprehension, uncertainty, loneliness and mass-hysteria are the common offshoots since COVID-19 began ([@bib0035]), as billions are quarantined at their homes, borders sealed and economies crashing down. Various studies have already mentioned a direct psychological impact on the vulnerable populations like elderly, migrants, homeless and also the frontline workers including the health care staff ([@bib0070]; [@bib0415]). High workload, absenteeism, burnout and guilt contribute to these outcomes in such individuals. Incidence of depression, anxiety and suicidality have been reported across many countries, compounded by the effects of the lockdown ([@bib0210]). Most studies from China, one of the first hit countries in this outbreak, have stressed on the importance of integrating online and community-based mental health services into the public health infrastructure as an attempt to combat the aftermath of this infection ([@bib0100]; [@bib0220]).

Even though the social and psychological effects have been studied to some extent, the direct effects of the SARS-CoV-2 on the central nervous system and role of psychoneuroimmunity are largely unknown. It is a well-established fact that immunity plays a major role in the genesis and severity of COVID-19. Supporting evidence includes the inverse relationship between lymphocyte counts, C-reactive protein (CRP) and Erythrocyte Sedimentation rate (ESR) levels and the severity of infection. Mortality has been associated with poor antibody titer in response to the infection ([@bib0320]). Neuro-invasive properties of the virus have been linked to respiratory failure and fatality rate ([@bib0205]). Also, convalescent plasma exchange is emerging as a promising therapy ([@bib0170]). Keeping in mind that the earlier outbreaks caused by different types of Coronavirus (CoV) (Severe Acute Respiratory Syndrome, SARS and Middle East Respiratory Syndrome, MERS) have produced varied neuropsychiatric manifestations, it is logical to assume that COVID-19 carries the same risk too. They mostly include acute meningoencephalitis, anosmia, manic-depressive disorders, demyelination, agitation and delirium ([@bib0145]). Similar findings have been found in the H1N1 influenza outbreaks of Europe, Zika outbreak in Brazil and earlier the Nipah infection in Singapore. In addition, complex and generalized seizures, encephalopathy, Guillain-Barre syndrome (GBS) and peripheral neuropathies have been reported in these viral infections (BY [@bib0260]; [@bib0105]).

The neurotropism of SARS-CoV-2 is still under debate. However, animal studies using nasal inoculation has clearly shown the trans-cribrial spread of the virus, with proliferation in the oligodendrocytes and endothelial cells. Post-mortem sections of pyriform cortex, basal ganglia and hypothalamus have shown the viral particles ([@bib0055]). Clinically, the neuropsychiatric manifestations of COVID-19 can be either acute or chronic, the latter will become more apparent as the cases increase globally. SARS-CoV-2 belongs to the same group of beta-coronaviruses as SARS and MERS. It also shares 85 percent identical nucleotide sequence with the SARS virus and has similar clinical characteristics ([@bib0375]). Hence, understanding its clinical attributes on the nervous system is possible in light of the studies done on its earlier congeners. As the world struggles towards a biological cure or vaccination, understanding the putative mechanisms and effects of the novel coronavirus on nervous tissue and mental health will be vital for its holistic management. This narrative review (based on data from January-May 2020), attempts to highlight the potential routes of CNS spread, the neuropsychiatric sequelae and possible pathophysiological mechanisms as per the studies done in the earlier coronavirus outbreaks. For the sake of clarity, henceforth throughout the article the novel coronavirus causing COVID-19 will be referred to as SARS-CoV-2, whereas its earlier congener causing SARS will be referred to as SARS-CoV.

2. Neural spread of COVID-19: the possible routes {#sec0010}
=================================================

The SARS-CoV-2 is reported to be functionally analogous to the SARS-CoV (causative agent of SARS). The usual cellular route is viral binding to Angiotensin Converting Enzyme (ACE)-2 receptor which is widely distributed along the respiratory and gastrointestinal epithelium as well as the endothelial cell surface. The spread to central nervous system has been correlated with increased age, high viral load, poor immunity, administration of glucocorticosteroids, history of neurotrophic viral infection in the past and increased hospitalization ([@bib0330]). Both animal and human models studying SARS-CoV have reported various possible neural pathways. The initial viral spread is hematogenous. In rodents, the virus has been detected in olfactory bulb 4 days after nasal inoculation and after 40 days in the pyriform cortex ([@bib0275]). In another study by the same group, destruction of olfactory bulb prevented the neural dissemination of the coronavirus. It showed that neural proliferation can happen in the cells of cortex, hypothalamus, thalamus, amygdala, basal ganglia and interestingly also in the brain stem ([@bib0280]). Dinein and kinesin are the two proteins that help in anterograde and retrograde transmission of the virus in neurons. The nucleus of the solitary fascicle in brainstem (that receives information from the chemoreceptors to alter the respiratory effort) is one of the important sites of viral load during post-mortem in animal models ([@bib0405]). This has been postulated as a putative theory how the virus can impair breathing-effort apart from the pulmonary involvement. Labored breathing or dyspnea is a direct clinical antecedent to Acute Respiratory Distress Syndrome (ARDS) in COVID-19, which in turn is linked to morbidity and mortality ([@bib0135]).

3. Neuropsychiatric manifestations of COVID-19: summary of current evidence {#sec0015}
===========================================================================

During the first wave of infection in China, [@bib0065] described the epidemiological and clinical characteristics of 99 patients with SARS-CoV-2 pneumonia. 9 percent and 4 percent of them had confusional state and headache respectively. Few months later, [@bib0225] retrospectively analyzed 214 patients with molecular diagnosis of COVID-19 from three different hospitals. 36.4 percent had neuropsychiatric symptoms, which were differentiated into central, peripheral/musculoskeletal and psychological. The central were commonest, with dizziness and headache being most prevalent. Dysgeusia, anosmia and muscle pain were most common among the peripheral symptoms. Anxiety, depression and delirium were the common psychiatric manifestations. The neurological symptoms had direct relation with the severity of the illness, serum antibody titer and blood lymphocyte counts. Also, though strokes, encephalopathies and peripheral neuropathies were rare (2 percent of the neuropsychiatric complaints), they were present in the elderly and immunocompromised group. A specific sub-group had ataxia and gait disturbances who also showed decreased CRP, impaired renal functions, poor oxygen saturation and increased need for ventilation. This was again a pointer towards brain-stem involvement. Similar blood findings have been found in children with CoV-2 infection and encephalitis ([@bib0230]). It has been postulated that decreased peripheral lymphocytes can either be due to poor immunological response altogether or increased CNS tissue migration. In SARS pneumonia with related clinical findings, Granulocyte Macrophage Colony-stimulating factor (GM-SCF) had been tried as a therapeutic agent, as it helps in the generation and propagation of CNS-targeted monocytes ([@bib0365]). On similar lines, peripheral lymphocyte counts, CRP and ESR have been used as prognostic markers in COVID-19 pneumonia and GM-CSF is popularized in research as a potential therapeutic target to prevent neuropsychiatric sequalae ([@bib0440]). The various neuropsychiatric manifestations that have so far been reported in COVID-19 are detailed below. As data is still emerging, various case reports and series mentioned in the literature do not necessarily imply causation but can highlight the associative neuropsychiatric impact.

3.1. Delirium and confusional states {#sec0020}
------------------------------------

Impaired sensorium ranging from mild drowsiness to delirium has been reported in few older adults hospitalized due to SARS-CoV-2 pneumonia, when compared to the younger participants ([@bib0215]). They had associated comorbidities and increased Pulmonary Severity Index (PSI). In another case series of older adults with premorbid cognitive decline ([@bib0040]), delirium was observed with COVID-19 infection which necessitated ICU admission. Unique features seen were alogia, abulia, rigidity and increased inflammatory markers. Obviously, pre-existing cognitive deficits, age, lack of stimulation, metabolic disturbances, urinary retention, constipation and prolonged hospitalization might be the associated contributing factors. Intensive care unit (ICU) delirium management and that during mechanical ventilation have been included in various treatment guidelines for COVID-19 ([@bib0410]). Especially in palliative care settings for COVID-19, among the most severely ill patients and elderly, the prevalence of delirium has been high. Tissue hypoxia, desaturation, neuro-inflammatory cytokines (regulating the 'cytokine storm' of SARS-CoV-2) and use of hydroxychloroquine has been associated with prolonged delirium in these patients ([@bib0400]). Effective management of sleep disturbance and early correction of sensorium are reported to be vital in post intensive care syndrome (PICS) and decreasing morbidity. Melatonin is being studied to have a promising role for the same in COVID-19 patients ([@bib0430]).

3.2. Dysfunction of olfaction and taste sensation {#sec0025}
-------------------------------------------------

During the SARS outbreak, studies have shown its affinity for the nasal ciliary epithelium. This property has been theorized to be common in the CoV group ([@bib0080]). In fact, the ACE-2 receptor that is the target for SARS-CoV-2 is expressed in the olfactory lining as well. This might be a probable mechanism for anosmia or hyposmia early in the COVID-19 infection, though the exact pathways are still being studied. The proportion of cases having olfactory and gustatory disturbances have ranged from 12 to 32 percent in a multi-site European study of COVID-19 cases ([@bib0200]). Olfactory dysfunction has even been considered as a biomarker for COVID-19 infection ([@bib0245]). They proposed that the predilection for the gustatory chemoreceptors and the higher order centers involved in taste and smell perception are more for the SARS-CoV-2 than its earlier congeners. Hyposmia has also been proposed as an early marker of neurological involvement in COVID-19 based on a European case-series, though structured research is yet to be done ([@bib0360]). Post-viral olfactory syndrome, a known complication of Influenza and Herpes virus infections, can also be associated with COVID-19, as the cribriform plate penetration and pyriform cortex involvement is common for all.

3.3. Acute psychosis and manic disorders {#sec0030}
----------------------------------------

So far, there have been only two case reports mentioning acute psychotic disturbances in cases of COVID-19, one of whom had schizophrenia ([@bib0115]; [@bib0445]). However, many known patients of schizophrenia have had exacerbations after getting affected with SARS-CoV-2 even while on medications ([@bib0425]). Whether there is a neuro-biological basis to it is unclear. The study by [@bib0225] mentioned people to have behavioural disturbances. SARS infection has been associated with acute psychiatric manifestations with increased antibody titer, which points out a probable relationship between coronavirus infections and psychosis ([@bib0075]). The CoV also proliferates in the limbic structures, as shown in animal models that further supports its association with behavior ([@bib0345]). Also, there has been debate whether vertical transmission is likely in COVID-19 positive mothers that can increase the neuro-developmental risk of psychosis in their off springs, similar to influenza ([@bib0290]). As multiple issues like drug compliance, lack of review, poor awareness and stress diathesis are involved during any biological disaster, it is difficult to conceptualize a direct link between increase of pre-existing psychiatric illnesses and the neurotropic effects of the virus.

3.4. Encephalitis and encephalopathies {#sec0035}
--------------------------------------

The classic [@bib0370] during the Spanish flu pandemic traditionally marks the association of viral infections and the brain. It was characterized by increased somnolence, behavioral disturbances, catatonic states and movement disorders. Similar encephalitis sequelae with altered consciousness have been reported during the H1N1 influenza and MERS infection ([@bib0020]). Though initially reported as a rare association in the current pandemic, multiple case reports of encephalitis have been reported since the first wave of infection. [@bib0255] reported the first case of meningoencephalitis in a COVID-19 patient with recent onset convulsions, who showed hyperintensity of bilateral mesial temporal lobes on brain imaging. Of special interest was a case of acute necrotizing haemorrhagic encephalopathy in a woman affected with COVID-19 where magnetic resonance tomography (MRI) of the brain showed rim-enhancing lesions in bilateral thalami, medial temporal lobes and sub-insular regions ([@bib0285]). The 'cytokine storm' responsible for ARDS and multi-organ dysfunction syndrome (MODS) in COVID-19 is marked by the surge of inflammatory cytokines in the circulation namely Interleukins (IL)-6, 8, 10, 18, Tumour Necrosis Factor (TNF)-alpha, Interferon-gamma and GM-CSF ([@bib0235]). Most of these factors were increased in 20 percent of COVID-19 positive cases in the study reported by [@bib0060],[@bib0065],[@bib0070]), who were diagnosed to have persistent encephalopathy. The association of exaggerated cell-mediated immunity with encephalitis has been studied in SARS as well ([@bib0150]). Especially in the COVID-19 patients receiving intensive care and ventilation, increased somnolence, agitation and confusion have been seen in those who had increased blood cytokines ([@bib0420]). Further, factors like pre-existing cognitive deficits, age and chronic psychiatric illness can increase the post-ICU recovery time and lead to long-lasting neuropsychological sequelae in such patients. Overall, encephalopathy has been considered to be the most serious acute neurological effect of COVID-19, as steroids (an important component of treatment) are restricted due to the pulmonary decompensation.

3.5. Acute cerebrovascular events {#sec0040}
---------------------------------

In the retrospective study by [@bib0225] among SARS-CoV-2 pneumonia cases, six patients reported acute cerebrovascular accident (CVA), in which most were ischemic strokes that developed within a week of pulmonary presentation. Another study of neurological symptoms in COVID-19 mentioned acute CVA to be more associated with the elderly, lower platelet count and increased D-dimer levels ([@bib0215],[@bib0220]). A case-series from United States (US) reported four elderly patients of COVID-19 who presented to the emergency with stroke, three of them had no prior CVA or associated risk factors ([@bib0030]). A probable mechanism might be viral effects on the ACE-2 receptors on the endothelial cells and platelets that can lead to hypertension and hyper-coagulable states respectively. But the cause or effect dilemma is debatable. On the other side, recurrent CVA has also been mentioned as a risk for severe COVID-19 infections. A pooled analysis of the published literature showed a 2.5-fold increase in the risk of severe CoV-2 infection in stroke patients ([@bib0015]). However, there was no significant association between stroke and mortality due to COVID-19. A case series by [@bib0270] reported five young patients presenting with stroke and comorbid COVID-19. A comparative theoretical analysis of non-human primate pathogenesis model in SARS, MERS and COVID-19 has implicated the SARS-CoV-2 spike protein to have a neuro-inflammatory role contributing to endothelial dysfunction and blood stasis ([@bib0310]). Though evidence is equivocal, this study warned about the potential role of ACE-inhibitors and ibuprofen in facilitating coronavirus infections. A recent study from Netherlands demonstrated that 31 percent of ICU patients developed thrombotic complications ([@bib0185]). Another study concluded that thromboplastin time-based clot waveform analysis (CWA) can determine hypercoagulability and risk of strokes associated with high viral loads in COVID-19 ([@bib0350]). Multiple reports of pulmonary embolism are also available ([@bib0060]; [@bib0090]). Keeping in mind this probable bi-directional relationship, separate guidelines have emerged for stroke management during the times of COVID-19. [@bib0175] has also proposed a Protected Code Stroke (PCS) framework during the ongoing pandemic which modifies the screening guidelines and includes rational use of personal protective equipment (PPE) and crisis management.

4. Possible neuropsychiatric sequelae of COVID-19: insights from earlier CoV studies {#sec0045}
====================================================================================

The COVID-19 pandemic is still in its early stages. The human-human transmission is higher than its earlier congeners ([@bib0330]) and the projected spread is ominous. As efforts for containment are on the rise, the upcoming months and years will add more to the understanding of long-term neuropsychiatric sequelae in COVID-19. Even if that affects a less proportion of cases, it is going to be associated with an immense public health burden. The SARS and MERS outbreaks also had far-reaching consequences that included chronic encephalopathies, neuromuscular disorders, neuropathies, demyelinating and degenerative conditions occurring long time after the initial presentation ([@bib0155]). As health-care priorities change with the timing of the pandemic, the initial flattening of curve might be assuring for the spread but at the same time brings about more serious and chronic manifestations of the infection, that remain mostly unknown till date. Though the data of long-term manifestations is yet not available for COVID-19, a few possible long-term neuropsychiatric conditions are proposed based on similar occurrences in the past CoV outbreaks.

4.1. Neuromuscular disorders {#sec0050}
----------------------------

Viral infections involving the brain are known to cause myopathy, neuropathy, GBS and brainstem encephalitis ([@bib0025]). These often take a month to manifest after the respiratory complaints. Multiple sclerosis patients had shown worsening during the SARS-Co-V infection and post-mortem studies have shown increased viral ribonucleic acid (RNA) load. A study by [@bib0405] attributed the demyelinating effect of coronaviruses to tissue hypoxia, direct neuronal injury, neuro-inflammation and major histocompatibility complex (MHC) mediated cell-mediated-immune (CMI) response to the virus. Murine models have shown the neuro-muscular concentration of the viruses to be strain dependent ([@bib0045]). Peripheral neuropathies in COVID-19 have been reported in few cases across the globe ([@bib0005]). A comprehensive review of neurological symptoms in coronavirus diseases mentions COVID-19 as a potential risk factor for long-term demyelinating and neuromuscular conditions ([@bib0355]).

4.2. Chronic psychiatric conditions {#sec0055}
-----------------------------------

There have been worsening of pre-existing psychiatric conditions namely mood and bipolar disorders, especially in the vulnerable populations. Increased incidence of depression, anxiety, adjustment disorders, acute stress reaction, somatization and obsessive-compulsive disorders have also been reported ([@bib0300]). Whether they are due to the adverse psychosocial situations and uncertainty of the pandemic crisis or whether the virus has a direct effect on the brain contributing to this, has not been well studied. Animal models have shown increased behavioral problems and poor performance in maze-finding, social play, mating and learned helplessness tasks after nasal inoculation of coronavirus ([@bib0130]). The translation to humans is still far-fetched. The mood disorders consequent to the SARS epidemic were related to host immune reaction ([@bib0155]). Recent studies among COVID-19 patients have found greater occurrence of depressive and anxiety disorders in people who are in quarantine, front-line workers or among family members of affected patients ([@bib0295]). However, the biological markers for same have not yet been studied. [@bib0265] while studying people with SARS-CoV infection, found exacerbations of mood disorders and psychosis in the long run but no association with the typology, mood polarity or suicidality. However, pandemic responses have classically been associated with marked increase in psychiatric morbidity. There has been specific rise in pain, depressive, obsessive compulsive disorders (OCD) and post-traumatic stress disorders (PTSD). The PTSD following such biological disasters might often be complex and chronic, unlike the commonly described ones. As time progresses, with the global burden of SARS-CoV-2 infection, more data on the psychiatric consequences of this pandemic are expected to come.

4.3. Neurodegenerative disorders {#sec0060}
--------------------------------

There is a theoretical risk for any coronavirus infected patient to develop Parkinson's like features, as the virus has been shown to proliferate in the basal ganglia in murine models ([@bib0120]). Borrowing from the motor involvement in 'encephalitis lethargica', movement disorders can be potential risk for any neurotrophic viral infection. Anti-CoV antibodies found in the cerebrospinal fluids of patients with motor disorders might have been incidental ([@bib0110]), as no clear literature is present about association of clinical Parkinson's disease with CoV infections. Also, considering coronavirus can stay latent in neural tissue for a long time ([@bib0160]), there might be a plausible risk for chronic degenerative conditions like dementia in the long run.

4.4. Eplilepsy {#sec0065}
--------------

Encephalopathy or cerebral edema consequent to CoV pathogenesis can lead to new-onset seizures or reactivation of latent epilepsy ([@bib0405]). The associated psychological stress can also be a triggering factor. A couple of case reports mention patients with COVID-19 presenting with generalized tonic-clonic seizures ([@bib0165]; [@bib0335]). One however had the primary diagnosis of encephalitis. Drug compliance risks during pandemics can increase the risk of status epilepticus, as reported earlier during the SARS outbreak ([@bib0195]). Certain anti-virals like remdesavir and lopinavir that have been used in COVID-19 patients can have cytochrome-based interactions with common anti-epileptics. The direct epileptogenic potential of CoV is however not established.

5. Neuropsychiatric effects of COVID-19: possible pathogenic mechanisms {#sec0070}
=======================================================================

Even though research in this field has just begun, based on the pathogenic models of the earlier CoV infections, here are some possible mechanisms in which SARS-CoV-2 might cause the above-mentioned manifestations. These are summarized with the evidence as under ([Table 1](#tbl0005){ref-type="table"} ).Table 1Possible mechanisms of pathogenesis for the neuropsychiatric manifestations of COVID-19.Table 1Mechanism of pathogenesisDetailsNeuropsychiatric effectsDirect injury (Blood circulation)\
([@bib0190]; [@bib0095])•Exaggerated immune response•Cytokines increasing blood-brain-barrier (BBB) permeability•Encephalopathy•Delirium and acute confusional stateDirect injury (Neuronal route)\
([@bib0250]; [@bib0050])•Predilection for olfactory epithelium, bulb and vagal centers•Anterograde and retrograde neural proliferation via dynein and kinesin•Structural preference for the forebrain, basal ganglia and hypothalamus•Anosmia•Dysguesia•Psychiatric disordersHypoxic injury\
([@bib0010]; [@bib0140])•Impaired pulmonary exchange and pulmonary oedema can cause cerebral hypoxia•Cerebral oedema, vasodilation, ischaemia and vascular congestion•Increased intracranial pressure•Encephalopathy•Somnolence•Coma•Headache•ConfusionDysregulated immunomodulation\
([@bib0125]; [@bib0235]; [@bib0380])•Cytokine storm (surge of peripheral IL-6,8,10,18, TNF-alpha, etc.)•Systemic Inflammatory Response Syndrome (SIRS)•Upregulation of oligodendrocytes and astrocytes (increased release of IL-15, TNF-alpha)•Leaky BBB•Disturbed neurotransmission•Encephalitis•MODS•Acute psychosis•SeizuresImmune cell transmigration to CNS\
([@bib0385]; [@bib0095])•Increased neuro-inflammation•Microglial activation•Neural and glial cells as latent 'viral-carriers'•Both acute and chronic neuropsychiatric effectsACE-2 and CoV spike protein interaction\
([@bib0240]; [@bib0395])•Vascular and endothelial damage•Hyper-coagulability•Increased blood-pressure•Microangiopathy•Cerebro-vascular accidents•Pulmonary and cerebral venous thromboembolism•Risk of chronic neurodegenerationAutoimmunity\
([@bib0180]; [@bib0315])•Molecular mimicry (cross-reaction of myelin, glia and beta-2 glycoprotein with viral epitopes•Demyelination•GBS•NeuropathyMiscellaneous\
([@bib0305])•High 'viral-latency' in CNS•Lack of MHC in brain•Homeostasis of neural issue•Persistent or relapsing-remitting neurological sequelae•Reactivation of seizures•Chronic psychiatric conditions

6. Conclusion {#sec0075}
=============

The numbers of cases infected with SARS-CoV-2 are rising each day. The public health systems of countries around the world were unprepared for a pandemic of such unprecedented scale. The pulmonary symptoms being on the forefront are the prime focus of treatment at present. It has however been shown from past outbreaks of CoV, that the neuropsychiatric symptoms arising out of the viral infection can add significantly to the health burden and quality of life ([@bib0085]; [@bib0145]). The emerging data related to the neuropsychiatric manifestations of COVID-19 are reviewed in this paper with other likely sequalae which has yet not been reported. As mentioned before, much of the current data is derived from case reports and series, which need to be interpreted with caution. They can imply association at maximum, not causation, which need more systematic researches. The proposed mechanisms are speculative, however as SARS-CoV-2 shares a lot of structural and functional similarities with the earlier congeners of the CoV family, studies done in SARS and MERS can help researchers glance into the current pathogenesis and thereby prepare management plans. The use of steroids in COVID-19 is increasing and they need to be monitored for the risk of worsening neuropsychiatric symptoms ([@bib0325]). Other immune-modulatory measures like intravenous immunoglobulin (IVIG), GM-CSF and interleukin-inhibitors are currently being tried in COVID-19 ([@bib0435]). Considering the putative neuro-inflammation involved, these agents might also hold a promise against the behavioral and neurological effects of the virus. The effect of immune response might be vital in exploring the interaction of the virus with the CNS and might help in the identification of therapeutic targets for drug development. Also, it might be helpful to understand the clinical differences in those with and without neurological sequelae and develop predictors or biomarkers of CNS involvement. The timeline of this pandemic is largely unknown, and the upcoming months are extremely important to use epidemiological and longitudinal studies, both to understand the viral effects on the mind-brain system and the possible solutions.
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